2021
BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
Allen C, Zeidan AM, Bewersdorf JP. BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML? Life 2021, 11: 465. PMID: 34071099, PMCID: PMC8224808, DOI: 10.3390/life11060465.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAcute myeloid leukemiaAntibody-based therapiesBispecific antibodiesSide effectsMalignant cellsBispecific T-cell engagersCytokine release syndromeCommon side effectsLeukemia-associated antigensT-cell engagersEarly encouraging resultsRelease syndromeGemtuzumab ozogamicinTreatment landscapeAML treatmentCell engagersAntigen escapeMyeloid leukemiaT cellsImmune responseFuture treatmentTherapyAntibodiesTreatmentCells
2020
Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)
Zeidan A, Wang V, Radich J, Bewersdorf J, Bhatt V, Sharon E, Gore S, Luger S, Litzow M. Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171). Blood 2020, 136: 1. DOI: 10.1182/blood-2020-137734.Peer-Reviewed Original ResearchUndetectable minimal residual diseaseChronic myeloid leukemiaMeasurable residual diseaseTyrosine kinase inhibitorsTKI discontinuationTKI therapyMinimal residual diseaseCML patientsResidual diseaseMyeloid leukemiaBristol-Myers SquibbPembrolizumab therapyAdverse eventsPD-1T cellsCML cellsAnti-PD-1/PD-L1 therapyBlast phase chronic myeloid leukemiaPilot phase II clinical trialThird-line tyrosine kinase inhibitorsAllogeneic hematopoietic stem cell transplantAnti-PD-1 monoclonal antibodyPD-1/PD-L1Anti-PD-1 pembrolizumabDetectable minimal residual disease
2018
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y, Bewersdorf JP, Stahl M, Zeidan AM. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? Blood Reviews 2018, 34: 67-83. PMID: 30553527, DOI: 10.1016/j.blre.2018.12.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHematopoietic stem cell transplantAcute myeloid leukemiaImmune checkpoint inhibitorsMyelodysplastic syndromeCheckpoint inhibitorsCell-based therapiesMyeloid leukemiaAllogeneic hematopoietic stem cell transplantCytotoxic T-lymphocyte-associated protein 4T-lymphocyte-associated protein 4Cell death protein 1Cell-based vaccinesNK cell therapyApplication of immunotherapyDeath protein 1Stem cell transplantAntibody-targeted therapyChimeric antigen receptorAntibody-based therapiesGemtuzumab ozogamicinDendritic cellsCell transplantImmunotherapeutic drugsT cellsClinical development